Aratana Suffers Setback on Canine Lymphoma Products
September 25, 2015
Aratana Therapeutics Inc. has sharply reduced its hopes for two canine lymphoma therapies but predicted a bright future for four other emerging products. The news, presented today during a conference call with market analysts, sent the veterinary biopharmaceutical company’s stock tumbling by 39 percent at the end of trading. Aratana intends to stay in the… Continue reading...